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Dementia includes several diseases characterized by acquired and irreversible brain
dysfunctions that interfere with daily life. According to the etiology, dementia can
be induced by poisoning or metabolic disorders, and other cases of dementia
have a clear pathogenesis. However, half of neurodegenerative diseases have an
unclear pathogenesis and etiology. Alzheimer’s disease (AD), Lewy body dementia
and frontal-temporal dementia are the three most common types of dementia. These
neurodegenerative diseases are characterized by the appearance of the following
specific protein inclusions: amyloid beta and tau in AD; α-synuclein in Lewy body
dementia; and tau, TDP-43, or FUS in frontal-temporal dementia. Thus far, studies
on the pathogenesis of dementia mainly focus aberrant inclusions formed by the
aforementioned proteins. As a historically heavily studied protein tau is likely to be
associated with the pathogenesis of several neurodegenerative diseases that cause
dementia. The role of tau in neurodegeneration has been unknown for many years.
However, both pathological and genetic analyses have helped tau become gradually
recognized as an important factor in the pathogenesis of tauopathy. Currently, especially
in the field of AD, tau is attracting more attention and is being considered a
potential target for drug development. In this review article, previously discovered
biochemical and pathological features of tau are highlighted, and current opinions
regarding the neurotoxicity of tau are summarized. Additionally, we introduce key amino
acid sequences responsible for tau neurotoxicity from our studies using transgenic
Caenorhabditis elegans. Finally, a new hypothesis regarding the roles of microtubule-
associated protein 2 (MAP2) and tau in the pathogenesis of tauopathy is discussed.
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TAU AND TAUOPATHY
Tau is a neuronal microtubule-associated protein and is primarily distributed in axons. It has
been suggested that the major function of tau is the stabilization of microtubules, but additional
studies on tau-knockout mice may reveal previously unknown functions in the future (Kimura
et al., 2013). The gene encoding tau in humans is MAPT, which is located on the long arm
of chromosome 17 (17q21). In the human adult brain, translated tau mRNA is spliced into
six isoforms: 0N3R, 0N4R, 1N3R, 1N4R, 2N3R and 2N4R. In the peripheral nervous system,
the longer tau isoform is expressed because of the exon 4a insertion. The microtubule-binding
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domains (MTBD) are located on the carboxyl terminal of tau and
consist of three or four 31 amino acid repeats (R; Mandelkow and
Mandelkow, 2012; West and Bhugra, 2015).
The relationship between tau and neurodegenerative
diseases was recognized through the characterization of
the components of neurofibrillary tangles (NFT). NFT are
one of the major pathological hallmarks in brains affected
by neurodegenerative diseases. Studies using human brains
suggested that the frequency and distribution of NFT are
highly correlated with neuronal loss and clinical symptoms
(Arriagada et al., 1992; Delacourte et al., 1999). In addition,
since 1998, more than 40 mutations in the tau gene were
identified in frontotemporal dementia with parkinsonism-17
(FTDP-17), which is a hereditary disease (Mandelkow
and Mandelkow, 2012). Therefore, aberrant tau protein
may have a causal relationship with the pathogenesis of
neurodegeneration.
Tau-inclusions are observed in the brains of patients affected
by several neurodegenerative diseases; therefore, these diseases
are termed tauopathies. One hereditary tauopathy is FTDP-17,
which is caused by mutations in MAPT (Goedert et al., 1998;
Spillantini and Goedert, 2000). Sporadic tauopathies include
several neurodegenerative diseases, such as Alzheimer’s disease
(AD), frontotemporal dementia, cortical basal degeneration,
progressive supranuclear palsy and others (Spillantini and
Goedert, 2013).
AD is the most common neurodegenerative disease that
causes senile dementia. The pathogenesis of AD is still largely
unknown (Mandelkow andMandelkow, 2012; West and Bhugra,
2015). There are three major pathological characteristics of AD,
including senile plaques formed by amyloid beta, NFT formed by
tau and neuronal loss. Beta and gamma secretases cleave amyloid
beta precursor protein (APP) to produce amyloid beta. Based on
the analysis of human brain tissue, senile plaques are detected
earlier than NFT in the cerebral neocortex (Braak and Braak,
1997; Hardy and Selkoe, 2002).
The importance of senile plaques in the pathogenesis of
AD was recognized by genetic analysis. Linkage studies of
familial AD revealed mutations in APP, PSEN1 (PS1) and
PSEN2 (PS2; Hardy and Selkoe, 2002). Meanwhile, PS1 and
PS2 were identified as key components of gamma-secretase,
one of the enzymes involved in the processing of APP
to amyloid beta (Hardy and Selkoe, 2002). These results
suggested that production of amyloid beta and formation
of senile plaques may cause AD in a direct or an indirect
manner. Tau pathology may be associated with amyloid
beta in the neocortex (Braak and Braak, 1997). Therefore,
it is widely hypothesized that amyloid beta is an upstream
causative factor in the pathogenesis of AD, which is known
as the amyloid beta cascade hypothesis (Hardy and Selkoe,
2002). Alternatively, previous findings indicated that tau is
essential for the pathogenesis induced by amyloid beta. For
example, using human APP transgenic-mice, Roberson et al.
(2007) suggested that suppressing endogenous tau effectively
ameliorated amyloid beta-induced neurotoxicity; thus, tau
may be a downstream effector of the amyloid beta cascade
and is a potential therapeutic target for AD (Giacobini and
Gold, 2013). In addition, tau is also essential for amyloid
beta-induced neurotoxicity in cultured cells (Rapoport et al.,
2002).
NEUROTOXIC SPECIES OF TAU
Because of the association between NFT and neuronal cell
loss, it is believed that formation of tau-inclusions may cause
toxicity to neuronal cells via an unknown pathway. To date,
the biochemical characteristics of accumulated tau (PHF-tau)
have been widely studied. Some abnormal post-translational
modifications have been identified, including phosphorylation,
ubiquitination, glycosylation and acetylation (Mandelkow and
Mandelkow, 2012). However, there is no conclusive evidence of
the involvement of tau-inclusions in neurotoxicity for any of the
post-translational modifications.
Another possible neurotoxic mechanism of tau was identified
in pathological studies. Studies on AD in the cerebral neocortex
suggested that the number of neurons lost is greater than
the number of neurons affected by NFT (Gomez-Isla et al.,
1997). In general, after neuronal death, NFT become ghost
tangles (Braak et al., 1994). Therefore, neuronal loss without
ghost tangles suggested that an NFT-independent mechanism
contributed to neurotoxicity in AD brains, especially in the
cerebral neocortex. Santacruz et al. (2005) suppressed tau
expression in a tau-transgenic mouse model using the Tet-Off
system, which effectively improved neuronal function but
did not alter the number of tau-inclusions. Gilley et al.
(2016) developed tau knock-in mouse lines and found that
neurotoxicity was induced without tau-inclusions. Wheeler
et al. (2015) also generated a human tau transgenic mouse
and observed behavioral deficits in the absence of NFT-like
inclusions. Moreover, human tau-A152T (a rare tau mutation)
transgenic mice showed neuronal dysfunction without insoluble
tau aggregates, suggesting a neurotoxic mechanism involving
soluble tau (Coppola et al., 2012; Maeda et al., 2016). Analyses
of Drosophila and Caenorhabditis elegans (C. elegans) also
suggested that the mechanism of neurotoxicity is not always
associated with the formation of NFT-like tau-inclusions, which
raised the possibility that toxic species of tau do not include
NFT-like tau-inclusions (Spittaels et al., 1999; Cowan and
Mudher, 2013; Xie et al., 2014). In addition, Kuchibhotla
et al. (2014) found that neurons bearing tau-inclusions
exhibited normal activity as detected by two-photon calcium
imaging.
Some hypotheses regarding specific toxic tau species have
been proposed. Currently, tau oligomers are an attractive
target. Lasagna-Reeves et al. (2010, 2011) prepared tau
oligomers seeded by amyloid beta aggregates and used the
oligomers to treat cultured cells and wild-type mice and
examined neurotoxicity. Their results suggested that tau
oligomers, rather than tau monomers and fibers, induced
significant neurotoxicity. Furthermore, they prepared an
anti-tau oligomer antibody, T22, to examine AD brains
and suggested that the number of T22 positive cells was
significantly higher than the normal controls. Similar results
from Patterson et al. (2011) suggested that there is a higher
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number of cells positive for the anti-tau dimer and oligomer
antibody TOC1 in AD brains than the normal controls.
However, because these anti-tau antibodies are cross-reactive
with tau fibers to some extent, we should be cautious
in our interpretation of the role of tau oligomers in the
pathogenesis of AD.
THE NEUROTOXIC SEQUENCES OF TAU
Because the formation of tau-inclusions takes months to a few
years, neuronal dysfunction may occur before neuronal death
(Miyasaka et al., 2005). Thus, to analyze tau neurotoxicity, the
best choice is to examine in vivo models with well-characterized
neural networks.
C. elegans is an organism that normally dwells in the
soil. C. elegans is a widely used experimental animal because
of its short lifespan, its convenient genetic manipulation
and its fully sequenced genome. Moreover, approximately
42% of human disease-related genes have orthologs
in the C. elegans genome. To date, many studies have
used C. elegans to research neurodegenerative diseases,
including tauopathy (Markaki and Tavernarakis, 2010;
Li and Le, 2013).
We constructed cDNA of full-length human tau and its
fragments downstream of the unc119 promoter to overexpress
tau in C. elegans neurons. The results suggested the aberrant
behavior (uncoordinated movement, UNC) was caused by
neuronal dysfunction due to tau expression. The UNC was
not induced by expression of other tau-unrelated proteins
such as GFP, which significantly exceeded tau expression
levels. Moreover, tau expression levels influenced UNC in a
dose-dependent manner and UNC was significantly worse in
the FTDP-17 mutants. These results suggested that transgenic
C. elegans is a good in vivo model for the study of neurotoxicity
induced by tau (Xie et al., 2014; Miyasaka et al., 2016).
Biochemical analysis suggested that expressed tau in
C. elegans is hyperphosphorylated and disassociated with
microtubules, which is similar to PHF-tau. In addition,
expressed tau is soluble in Triton X-100, Sarkosyl and RIPA
buffer, suggesting the absence of NFT-like tau-inclusions in the
C. elegans model. However, morphological analysis revealed
aberrant tortuous processes on the nerve fibers, which suggested
that neurotoxicity is independent of tau-inclusion formation
(Xie et al., 2014; Miyasaka et al., 2016).
Next, we asked which sequence is responsible for tau
neurotoxicity. The full-length, carboxyl terminal and amino
terminal of tau were separately overexpressed in the nervous
system of C. elegans. Then, neurotoxicity was evaluated using
the percentage of C. elegans exhibiting UNC. Neurotoxicity
was observed in tau-transgenic C. elegans overexpressing the
full length and carboxyl terminal but not in the animals
overexpressing the amino terminal. Moreover, the analysis of
tau isoforms revealed that four-repeat tau induced significantly
more severe neurotoxicity than three-repeat tau in transgenic
C. elegans. These results suggested that the carboxyl terminal
of tau, including MTBD, was responsible for neurotoxicity
(Xie et al., 2014).
THE CARBOXYL TERMINAL OF TAU
The structure of tau is mainly separated into two parts,
including the amino-terminal sequences and the carboxyl-
terminal sequences. As a microtubule-associated protein, the
carboxyl terminal of tau is notable because of the special
microtubule binding sites with repeats (Figure 1). Interestingly,
the carboxyl terminal of tau is also the key domain that
forms the core structure of NFT under pathological conditions
(Kondo et al., 1988; Wischik et al., 1988; Jakes et al., 1991).
These facts suggested that there may be competition between
the physiological functions and pathological aggregation of tau
(Kadavath et al., 2015).
Xu et al. (2016) found that exposing the carboxyl terminal
may promote tau aggregation. Additionally, a portion of the
carboxyl terminal of tau is enough to form Alzheimer’s filaments
(von Bergen et al., 2000). In addition to tau aggregation,
MTBD is enough to induce neurotoxicity in tau pathological
models (Sanders et al., 2014; Decker et al., 2015; Hochgräfe
et al., 2015). Most MAPT mutations, such as G272V, V337M
and R406W and post-translational modifications including
acetylation, O-GlcNAc modification and phosphorylation, are
located on the carboxyl terminal of tau (Goedert et al., 1998;
Spillantini and Goedert, 2000; Mandelkow and Mandelkow,
2012; Yuzwa et al., 2012). Acetylation of K280, which is localized
in MTBD, accelerates pathological tau aggregation and increases
tau neurotoxicity in vivo (Cohen et al., 2011; Gorsky et al., 2016).
Deletion of K280 strikingly enhances the aggregation propensity
and cellular toxicity of tau, despite a decrease in the expression
of 4R-tau (Khlistunova et al., 2006; Mocanu et al., 2008; Momeni
et al., 2009). Moreover, Taniguchi-Watanabe et al. (2016) found
different carboxyl-terminal band patterns in various tauopathies,
indicating a novel classification for each tau-related disease.
This increasing evidence provided us with insight into the close
relationship between the carboxyl-terminal sequences of tau and
the pathogenesis of tauopathies.
THE POTENTIAL RELATIONSHIP
BETWEEN MAP2 AND TAUOPATHY
As described above, the carboxyl-terminal sequences of tau
are closely involved in the pathogenesis of tauopathy. If these
findings are accurate, then another question should be asked.
Does microtubule-associated protein 2 (MAP2), which shares
carboxyl-terminal sequences with tau, also induce neurotoxicity
and associate with tauopathies? Under physiological conditions,
tau is located in the axons, whereas MAP2 is located in
the cell body and dendrites (Dehmelt and Halpain, 2005). In
brains affected by tauopathy, the somatodendrites containing
MAP2 overlap with the area where tau pathology is observed.
Thus, understanding the properties of MAP2 will help us better
understand the pathogenesis of tauopathy (Figure 1).
The relationship between tau and neurodegenerative diseases
has been widely studied. However, few reports link MAP2 to
human diseases. After tau was identified as the major component
of NFT, there were different opinions on whether MAP2 was also
a component of NFT. Kosik et al. (1984) prepared anti-MAP2
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FIGURE 1 | (A) The comparison of full-length amino acid sequences of tau (0N3R) and microtubule-associated protein 2c (MAP2c). Epitopes of anti-tau antibodies,
including AT8, AT100, AT180, pS262, PHF1, AP422 and T46, are shown. Note that MAP2 also has a similar amino acid sequence with the epitopes of some
antibodies that recognize the carboxyl-terminal region of tau. For consistency, in the article, the numbers of the amino acids in tau mutations and phosphorylated
sites correspond to the longest tau isoform 2N4R. (B) Table of functional and pathological features between tau and MAP2.
monoclonal antibodies and suggested that MAP2 may localize
to NFT using immunochemistry methods. Whereas Rosemblatt
et al. (1989) claimed that MAP2 is not located in NFT. The
results of Nukina et al. (1987) suggested that the contradiction
may be caused by cross-reactivity between anti-MAP2 antibodies
and tau.
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FIGURE 2 | The hypothesis of the potential involvement of MAP2 in the pathogenesis of tauopathy.
The amino terminal of tau projects from part of the core
structure of NFT and is gradually cut off with increasing
aggregation time (Miyasaka et al., 2005). In adult human brains,
MAP2 is mainly expressed as a 280 kDa isoform, which has
a longer amino-terminal projecting domain than tau and may
be more easily removed by proteases. Therefore, although the
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anti-MAP2 amino-terminal antibodies are not considered to
cross-react with tau, inaccurate results may be obtained due
to MAP2 degradation. To solve this issue, we focused on the
differences between homologous carboxyl-terminal sequences of
tau and MAP2, and prepared anti-MAP2 polyclonal antibodies,
which did not cross-react with tau. Using these new anti-MAP2
antibodies, we examined MAP2 localization in AD brains and
found that MAP2 remained in the tangle-bearing neurons, but
did not co-localize with NFT (Xie et al., 2014). Moreover, the
Sarkosyl-insoluble fractions from human AD brains and normal
controls were immunoblotted with tau and MAP2 antibodies.
The results suggested that tau, but not MAP2, was deposited
in the Sarkosyl-insoluble fractions from AD brains (Xie et al.,
2014). Although tau and MAP2 share homologous carboxyl-
terminal sequences, they experience different fates during NFT
formation.
Why do tau and MAP2 have different fates in AD brains?
To answer this question, we expressed and purified recombinant
tau and MAP2 from E. coli, and investigated their aggregation
properties. Tau aggregates in the presence of heparin in vitro,
which can be detected by Thioflavin T (ThT; Goedert et al.,
1996). Thus, the aggregation properties of tau and MAP2 were
compared with an in vitro aggregation method. The results
showed that the fluorescence of ThT increased by incubating tau
with heparin. However, whenMAP2 and heparin were incubated
together, the fluorescence remained low. The aggregated
fractions were further examined by atomic force microscope, and
we found that tau formed fibers, whereasMAP2 formed granules.
Therefore, tau andMAP2 have completely different properties of
aggregation (Xie et al., 2015).
Further, we constructed, expressed and purified a series
of tau and MAP2 mutants to identify their aggregation
abilities using the same methods described above. The results
suggested that the homologous carboxyl terminal of tau and
MAP2 are the key domains that determine their aggregation
properties. Exchanging three amino acids of the carboxyl-
terminal sequences can reverse their fiber formation abilities.
Therefore, the different aggregation properties between tau and
MAP2 are only determined by three amino acids around K280
(Xie et al., 2015).
We finally used transgenic C. elegans to examine and
compare the neurotoxicity of MAP2 and tau. The results
suggested for the first time that MAP2 also induced significant
neurotoxicity similar to tau. Interestingly, the key neurotoxic
sequences are in the homologous carboxyl terminal of MAP2
(Xie et al., 2014). Thus, MAP2 and tau both induced
neurotoxicity via their homologous carboxyl-terminal sequences
in vivo. However, MAP2 is not deposited in NFT and
does not form fibers comparable to tau (Xie et al., 2014,
2015). Therefore, fiber formation and neurotoxicity may be
unrelated.
CONCLUSIONS
Most of the studies on dementia focus on the proteins
forming specific pathological inclusions. However, it is unknown
whether the pathological inclusions are byproducts or causative
factors. Currently, genetic analysis is the most powerful tool
to identify causative factors in human diseases. However,
mutations in tau are not found in sporadic tauopathies,
including AD. We cannot exclude the possibility that the
pathogenesis of familial and sporadic tauopathies is different.
In familial hereditary tauopathy, aberrant tau inclusions
induce neurotoxicity because of mutations in the MAPT
gene. Whereas in sporadic tauopathy, especially in AD,
mutations in APP, PS1 and PS2, aging and other risk factors
produce amyloid beta that forms senile plaques and then
leads to tau pathology through unknown processes. Moreover,
amyloid beta toxicity mainly localizes to the somatodendritic
area where MAP2 is located. MAP2 may also be involved
in the pathogenesis of tauopathies, but it is difficult to
find MAP2 inclusions because of its weak fiber-formation
abilities. However, MAP2 can induce neurotoxicity via the
homologous carboxyl-terminal sequence, which may cause
neuronal dysfunction without leaving any pathological traces
(Figure 2).
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